BHVN
Price
$15.96
Change
-$0.52 (-3.16%)
Updated
Oct 17, 04:59 PM (EDT)
Capitalization
1.69B
32 days until earnings call
Intraday Buy/Sell Signals
IDYA
Price
$29.29
Change
+$1.60 (+5.78%)
Updated
Oct 17, 04:59 PM (EDT)
Capitalization
2.56B
25 days until earnings call
Intraday Buy/Sell Signals
Interact to see
Advertisement

BHVN vs IDYA

Header iconBHVN vs IDYA Comparison
Open Charts BHVN vs IDYABanner chart's image
Biohaven
Price$15.96
Change-$0.52 (-3.16%)
Volume$16.47K
Capitalization1.69B
IDEAYA Biosciences
Price$29.29
Change+$1.60 (+5.78%)
Volume$160.67K
Capitalization2.56B
BHVN vs IDYA Comparison Chart in %
BHVN
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
IDYA
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
BHVN vs. IDYA commentary
Oct 18, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is BHVN is a Hold and IDYA is a Hold.

Interact to see
Advertisement
COMPARISON
Comparison
Oct 18, 2025
Stock price -- (BHVN: $16.48 vs. IDYA: $27.69)
Brand notoriety: BHVN and IDYA are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: BHVN: 90% vs. IDYA: 85%
Market capitalization -- BHVN: $1.69B vs. IDYA: $2.56B
BHVN [@Biotechnology] is valued at $1.69B. IDYA’s [@Biotechnology] market capitalization is $2.56B. The market cap for tickers in the [@Biotechnology] industry ranges from $106.87B to $0. The average market capitalization across the [@Biotechnology] industry is $2.06B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

BHVN’s FA Score shows that 0 FA rating(s) are green whileIDYA’s FA Score has 0 green FA rating(s).

  • BHVN’s FA Score: 0 green, 5 red.
  • IDYA’s FA Score: 0 green, 5 red.
According to our system of comparison, IDYA is a better buy in the long-term than BHVN.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

BHVN’s TA Score shows that 5 TA indicator(s) are bullish while IDYA’s TA Score has 5 bullish TA indicator(s).

  • BHVN’s TA Score: 5 bullish, 4 bearish.
  • IDYA’s TA Score: 5 bullish, 2 bearish.
According to our system of comparison, IDYA is a better buy in the short-term than BHVN.

Price Growth

BHVN (@Biotechnology) experienced а -4.35% price change this week, while IDYA (@Biotechnology) price change was +3.36% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +1.56%. For the same industry, the average monthly price growth was +16.03%, and the average quarterly price growth was +79.42%.

Reported Earning Dates

BHVN is expected to report earnings on Nov 18, 2025.

IDYA is expected to report earnings on Nov 11, 2025.

Industries' Descriptions

@Biotechnology (+1.56% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
IDYA($2.56B) has a higher market cap than BHVN($1.69B). IDYA YTD gains are higher at: 7.743 vs. BHVN (-55.877). IDYA has higher annual earnings (EBITDA): -380.2M vs. BHVN (-792.68M). IDYA has more cash in the bank: 670M vs. BHVN (405M). IDYA has less debt than BHVN: IDYA (26.6M) vs BHVN (292M). IDYA has higher revenues than BHVN: IDYA (7M) vs BHVN (0).
BHVNIDYABHVN / IDYA
Capitalization1.69B2.56B66%
EBITDA-792.68M-380.2M208%
Gain YTD-55.8777.743-722%
P/E RatioN/AN/A-
Revenue07M-
Total Cash405M670M60%
Total Debt292M26.6M1,098%
FUNDAMENTALS RATINGS
BHVN vs IDYA: Fundamental Ratings
BHVN
IDYA
OUTLOOK RATING
1..100
2172
VALUATION
overvalued / fair valued / undervalued
1..100
56
Fair valued
57
Fair valued
PROFIT vs RISK RATING
1..100
10066
SMR RATING
1..100
100100
PRICE GROWTH RATING
1..100
5341
P/E GROWTH RATING
1..100
100100
SEASONALITY SCORE
1..100
5050

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

BHVN's Valuation (56) in the Pharmaceuticals Major industry is in the same range as IDYA (57) in the null industry. This means that BHVN’s stock grew similarly to IDYA’s over the last 12 months.

IDYA's Profit vs Risk Rating (66) in the null industry is somewhat better than the same rating for BHVN (100) in the Pharmaceuticals Major industry. This means that IDYA’s stock grew somewhat faster than BHVN’s over the last 12 months.

IDYA's SMR Rating (100) in the null industry is in the same range as BHVN (100) in the Pharmaceuticals Major industry. This means that IDYA’s stock grew similarly to BHVN’s over the last 12 months.

IDYA's Price Growth Rating (41) in the null industry is in the same range as BHVN (53) in the Pharmaceuticals Major industry. This means that IDYA’s stock grew similarly to BHVN’s over the last 12 months.

IDYA's P/E Growth Rating (100) in the null industry is in the same range as BHVN (100) in the Pharmaceuticals Major industry. This means that IDYA’s stock grew similarly to BHVN’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
BHVNIDYA
RSI
ODDS (%)
N/A
N/A
Stochastic
ODDS (%)
Bearish Trend 2 days ago
79%
Bullish Trend 2 days ago
74%
Momentum
ODDS (%)
Bullish Trend 2 days ago
77%
Bullish Trend 2 days ago
75%
MACD
ODDS (%)
Bullish Trend 2 days ago
78%
Bullish Trend 2 days ago
82%
TrendWeek
ODDS (%)
Bearish Trend 2 days ago
77%
Bullish Trend 2 days ago
77%
TrendMonth
ODDS (%)
Bullish Trend 2 days ago
76%
Bullish Trend 2 days ago
81%
Advances
ODDS (%)
Bullish Trend 3 days ago
74%
Bullish Trend 3 days ago
78%
Declines
ODDS (%)
Bearish Trend 5 days ago
76%
Bearish Trend 8 days ago
77%
BollingerBands
ODDS (%)
Bearish Trend 2 days ago
77%
Bearish Trend 2 days ago
78%
Aroon
ODDS (%)
Bearish Trend 2 days ago
84%
Bullish Trend 2 days ago
82%
View a ticker or compare two or three
Interact to see
Advertisement
BHVN
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
IDYA
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
MIGMX32.86N/A
N/A
MFS Massachusetts Inv Gr Stk R1
EMAAX16.68N/A
N/A
Gabelli Entpr Mergers & Acquisitions A
TAVFX72.08N/A
N/A
Third Avenue Value Instl
TWQIX16.77N/A
N/A
Transamerica Large Cap Value I
KCGIX24.61N/A
N/A
Knights of Columbus Large Cap Growth I

BHVN and

Correlation & Price change

A.I.dvisor indicates that over the last year, BHVN has been loosely correlated with SYRE. These tickers have moved in lockstep 57% of the time. This A.I.-generated data suggests there is some statistical probability that if BHVN jumps, then SYRE could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To BHVN
1D Price
Change %
BHVN100%
-5.07%
SYRE - BHVN
57%
Loosely correlated
+0.23%
CGON - BHVN
53%
Loosely correlated
-2.79%
XENE - BHVN
50%
Loosely correlated
+0.64%
IDYA - BHVN
48%
Loosely correlated
-2.43%
ELVN - BHVN
48%
Loosely correlated
+0.09%
More

IDYA and

Correlation & Price change

A.I.dvisor indicates that over the last year, IDYA has been loosely correlated with IMNM. These tickers have moved in lockstep 59% of the time. This A.I.-generated data suggests there is some statistical probability that if IDYA jumps, then IMNM could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To IDYA
1D Price
Change %
IDYA100%
-2.43%
IMNM - IDYA
59%
Loosely correlated
+0.86%
NRIX - IDYA
58%
Loosely correlated
-3.09%
CGON - IDYA
58%
Loosely correlated
-2.79%
NUVL - IDYA
58%
Loosely correlated
+0.87%
OCUL - IDYA
57%
Loosely correlated
+2.22%
More